Effect of age on treatment outcomes of first‐line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma
Geriatrics & Gerontology International · 2025-08 · 25 (8) · 1082-1088
DOI: 10.1111/ggi.70105 ↗Kurz gefasst
Fachartikel in der Zeitschrift Geriatrics & Gerontology International, online erschienen am 18.06.2025. Verfasst von Hiroki Ishihara und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Saiseikai Kawaguchi General Hospital, Kawaguchi, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Immune Checkpoint Inhibitors, Kidney Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Aim
To clarify the association between age and treatment outcomes of first‐line immune checkpoint inhibitor (ICI) combination therapy for previously untreated advanced renal cell carcinoma (RCC).
Methods
We retrospectively evaluated the clinical data of 246 patients who received ICI combination therapy as a first‐line systemic therapy for advanced RCC. The patients were divided into three groups based on age as follows: Age I, ≤ 65 years; Age II, > 65 to ≤ 75 years; and Age III, > 75 years. Survival, tumor response, and toxicity were compared among the three groups.
Results
Of 246 patients, 111 (45%) were treated with ICI dual combination therapy. In them, progression‐free survival, overall survival, and objective response rate were not significantly different among age‐based subgroups ( P > 0.05). The development rates of adverse events of any grade and those of grade ≥3 and the rates of treatment interruption, discontinuation, and glucocorticoid use were not significantly different among the groups ( P > 0.05). In the remaining 135 patients (55%) receiving combinations of ICIs with tyrosine kinase inhibitors, similar findings were observed: the survival, tumor response, and toxicity profiles were comparable among age‐based subgroups ( P > 0.05).
Conclusion
The effectiveness and safety profiles of first‐line ICI combination therapy did not deteriorate, even in older patients. These findings suggest that ICI combination therapy for RCC should not be avoided because of chronological age alone. Geriatr Gerontol Int 2025; 25: 1082–1088 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Saiseikai Kawaguchi General Hospital, Kawaguchi, Japan.
- Department of Urology, Tokyo Women's Medical University, Shinjuku-ku, Japan.
- Department of Urology, Tokyo Women's Medical University Adachi Medical Center, Adachi-ku, Japan.
- Department of Urology, Jyoban Hospital, Iwaki, Japan.
- Department of Urology, Saiseikai Kazo Hospital, Kazo, Japan.
ORCID-Profile: Hiroki Ishihara, Toshio Takagi
Zitieren
APA
Ishihara, H., Nishimura, K., Nemoto, Y., Mizoguchi, S., Nakayama, T., Fukuda, H., Shimmura, H., Hashimoto, Y., Yoshida, K., Iizuka, J., Kondo, T., & Takagi, T. (2025). Effect of age on treatment outcomes of first‐line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma. Geriatrics & Gerontology International, 25(8), 1082-1088. https://doi.org/10.1111/ggi.70105
Vancouver
Ishihara H, Nishimura K, Nemoto Y, Mizoguchi S, Nakayama T, Fukuda H, et al. Effect of age on treatment outcomes of first‐line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma. Geriatrics & Gerontology International. 2025;25(8):1082-1088. doi:10.1111/ggi.70105
BibTeX
@article{Ishihara2025,
author = {Ishihara, Hiroki and Nishimura, Koichi and Nemoto, Yuki and Mizoguchi, Shinsuke and Nakayama, Takayuki and Fukuda, Hironori and Shimmura, Hiroaki and Hashimoto, Yasunobu and Yoshida, Kazuhiko and Iizuka, Junpei and Kondo, Tsunenori and Takagi, Toshio},
title = {Effect of age on treatment outcomes of first‐line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma},
journal = {Geriatrics & Gerontology International},
year = {2025},
volume = {25},
number = {8},
pages = {1082--1088},
doi = {10.1111/ggi.70105}
}
EUVIMED